Status:

COMPLETED

Therapeutic Effects of Transcranial Alternative Current Stimulation (tACS) in Chronic Post Stroke Hemianopia

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Hemianopsia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Background: The most common visual field deficit after retro-chiasmatic lesions is homonymous hemianopia (HH), defined as the impossibility of seeing the contralesional visual hemisphere without ocula...

Detailed Description

Background: Focusing on low-level perceptual activities, and robust, controlled explorations with medium-sized cohorts, several studies have shown tACS effects related to oscillatory activity and int...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Patient aged 18 and over
  • Patient with homonymous lateral hemianopia with brain injury acquired for at least 3 months and at most 10 years after ischemic stroke, cerebral hematoma
  • Patient able to understand French both orally and in writing
  • Patient giving free, informed and written consent
  • Absence of a neurological disease interfering with the passing of tests
  • Non-inclusion criteria :
  • Patients subject to a legal protection measure (safeguarding of justice, guardianship and trusteeship, protected adults)
  • Pre-existing severe ophthalmological disorders, visual field disorders visual field disorders, monocular visual acuity less than 5/10, severe oculomotor disorders (post-stroke ophthalmological consultation less than at the time of inclusion)
  • Contraindication of tACS and / or magnetic resonance imaging (pacemaker or implantable defibrillator, intracranial electrodes or other intracranial implant, cranial vault anomalies facing stimulation electrodes (plates, prostheses, uncovered skull)
  • Pregnant women and nursing mothers
  • Recruitment in other interventional studies for the duration of the participation.
  • Non-affiliation to a social security scheme (excluding AME) or non-beneficiary of such a scheme
  • Healthy participants inclusion criteria are the following:
  • Healthy Subject 18 years and older
  • Healthy subject able to understand French both orally and in writing
  • Healthy subject who has given free and informed consent and writes
  • Healthy participants non-inclusion criteria are the following:
  • Severe neurological, psychiatric, physical, or ophthalmological disorders (binocular visual acuity less than 5/10, ophthalmological consultation less than one year old at the time of inclusion) that interfere with the normal performance of tests and study tasks
  • Contraindication to magnetic resonance imaging (pacemaker or implantable defibrillator, intracranial electrodes or other intracranial implant, abnormalities of the cranial vault opposite stimulation electrodes (plates, prostheses, uncovered skull)
  • Recruitment in other interventional studies for the duration of the participation.
  • Pregnant women and nursing mothers
  • Non-affiliation to a social security scheme (excluding AME) or non-beneficiary of such a scheme

Exclusion

    Key Trial Info

    Start Date :

    December 22 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 3 2025

    Estimated Enrollment :

    43 Patients enrolled

    Trial Details

    Trial ID

    NCT04043689

    Start Date

    December 22 2020

    End Date

    April 3 2025

    Last Update

    May 8 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    GH Pitié Salpêtrière

    Paris, France, 75013